Transgene to Present Data at 2004 ASCO Annual Meeting
12 Mayo 2004 - 8:45AM
PR Newswire (US)
Transgene to Present Data at 2004 ASCO Annual Meeting STRASBOURG,
France, May 12 /PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY;
Nouveau Marche: FR0005175080) today announced the scheduled
presentations of data on two product candidates at the American
Society of Clinical Oncology annual meeting, June 5-8, 2004 in New
Orleans, Louisiana. Mirjana Urozevic, MD, from the Department of
Dermatology, University Hospital, Zurich, Switzerland, will present
interim results of Transgene's Ad-IFN gamma product candidate
currently in a Phase I/II clinical trial in primary cutaneous
lymphoma. The Ad-IFN gamma abstract has been selected to receive a
2004 ASCO Foundation Merit Award. Patrick Squiban, MD,
Vice-President Medical and Regulatory Affairs of Transgene will
present interim results on the MVA-Muc1-IL2 cancer vaccine
currently in Phase II clinical trial for lung, prostate and kidney
cancer. Presentations: Title: "Phase I/II study of
adenovirus-interferon gamma (TG 1042) in primary cutaneous
lymphomas (CL)" Date and time of the session: June 6, 2004 - 11:00
am to 12:00 pm --------------------- Title: "MVA-Muc1-IL2 vaccine
immunotherapy for advanced non small cell lung cancer (NSCLC):
Interim Phase II Data" Date and time of the session: June 7, 2004 -
8:00 am to 12:00 pm About Transgene Transgene, based in Strasbourg,
France, is a biopharmaceutical company dedicated to the discovery
and development of therapeutic vaccines, immunotherapy products,
and delivery technologies for the treatment of diseases for which
there is no cure or adequate treatment at present, with a focus on
the treatment of cancer. Transgene has five products in clinical
development, two of which are in Phase II clinical trials, two in
Phase I/II and one that has completed Phase I clinical trial.
Transgene's proprietary vector technology platform consists of
adenovirus and poxvirus. DATASOURCE: Transgene CONTACT: Patrick
Squiban, MD, VP Medical & Regulatory Affairs of Transgene,
+33-3-88-27-91-73; Michael Long of Cohn & Wolfe,
+1-212-798-9775; Estelle Guillot-Tantay, +33-1-53-70-74-93, or
Laurence Heilbronn, +33-1-53-70-74-64, both of Image 7, all for
Transgene
Copyright